BRAF and neoplasm: The recurrentmelanoma was unresectable, and thus, a combined therapy with oral dabrafenib andtrametinib was applicable since the tumor had the BRAF mutation.38,39 The patientmaintained the stable disease with no local recurrence but with smalllymphadenopathy later in one and a half year after the initial surgery ofdacryocystectomy.